NautaDutilh successfully assisted Pharming Group N.V. with its EUR 125 million convertible bonds issue. The convertible bonds have a term of five years and a coupon of 3.00% per annum and will be listed on the Frankfurt Stock Exchange. Pharming will use the proceeds, among others, to replace and repay a current loan facility (and thereby significantly reduce its financings costs from 13% to 3%), accelerate expansion of production and commercial capability and to serve as funding for the launch of its recently acquired Leniolisib product.
Pharming is a specialty pharmaceutical company developing innovative products for the safe, effective treatment of rare diseases and unmet medical needs. Pharming’s lead product, RUCONEST® (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema attacks in patients in Europe, the US, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorisation.
NautaDutilh acted as Dutch counsel alongside Covington & Burling LLP. The NautaDutilh team consisted of Petra Zijp, Antonia Netiv, Sabrina Legerstee, Annefleur van Oel, Paul van der Bijl, Koen Biesma and Nina Kielman.